Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuroone Medical Technologies (NMTC) Research & Development (2017 - 2026)

Neuroone Medical Technologies filings provide 8 years of Research & Development readings, the most recent being $1.5 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 9.74% to $1.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.2 million, a 10.97% increase, with the full-year FY2025 number at $5.0 million, down 1.62% from a year prior.
  • Research & Development hit $1.5 million in Q1 2026 for Neuroone Medical Technologies, up from $1.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.9 million in Q2 2023 to a low of $1.0 million in Q4 2024.
  • Median Research & Development over the past 5 years was $1.3 million (2025), compared with a mean of $1.4 million.
  • Biggest five-year swings in Research & Development: skyrocketed 54.36% in 2023 and later plummeted 37.41% in 2024.
  • Neuroone Medical Technologies' Research & Development stood at $1.6 million in 2022, then decreased by 5.13% to $1.5 million in 2023, then crashed by 32.44% to $1.0 million in 2024, then skyrocketed by 38.66% to $1.4 million in 2025, then rose by 5.64% to $1.5 million in 2026.
  • The last three reported values for Research & Development were $1.5 million (Q1 2026), $1.4 million (Q4 2025), and $1.1 million (Q3 2025) per Business Quant data.